Condition

EGFR

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 17 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials17

Recruiting7

Common interventions25

Lead sponsors shown15

Clinical trials

17 shown

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCCNCT07462377 · 2026-03-31

Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)NCT06992739 · 2025-12-08

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLCNCT07742332 · 2025-11-25

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung CancerNCT07563205 · 2025-11-19

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKINCT07181499 · 2025-09-01

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationNCT06956001 · 2024-11-19

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung CancerNCT06755684 · 2024-11-07

Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLCNCT07802834 · 2026-11-01

NOT_YET_RECRUITING

Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLCNCT07807722 · 2026-09-21

NOT_YET_RECRUITING

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionNCT07128199 · 2025-12-22

ACTIVE_NOT_RECRUITING

The HER Project: HRD in EGFR-mutated NSCLCNCT07303218 · 2025-12-01

ACTIVE_NOT_RECRUITING

Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung CancerNCT07177092 · 2025-09-08

NOT_YET_RECRUITING

Development of a Fluorescent Visualization System for Non-visible Lung Cancer NodulesNCT06101394 · 2024-01-01

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid TumorsNCT06403436 · 2023-11-07

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted TherapiesNCT05370469 · 2022-08-25

ACTIVE_NOT_RECRUITING

To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung AdenocarcinomaNCT03656393 · 2018-08-31

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung CancerNCT01542437 · 2012-01-01

Common interventions

Leading sponsors

Peng Zhang 2 Allist Pharmaceuticals, Inc. 1 Betta Pharmaceuticals Co., Ltd. 1 EpiBiologics 1 GFPC Investigation 1 Hubei Cancer Hospital 1 Instituto Nacional de Cancerologia de Mexico 1 IRCCS San Raffaele 1 Jianxing He 1 Shenzhen People's Hospital 1 Stanford University 1 Taiho Oncology, Inc. 1 The First Affiliated Hospital of Xiamen University 1 TOLREMO therapeutics AG 1 University of Turin, Italy 1

Trial status mix

RECRUITING7

ACTIVE_NOT_RECRUITING3

NOT_YET_RECRUITING3

COMPLETED2

UNKNOWN2

Phase mix

PHASE29

PHASE33

PHASE12

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.